Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 4Lymphoid 3Gastrointestinal 3Tumor-Agnostic 2Plasma cell 2Thoracic 1Sarcoma 1Genitourinary 1CNS 1

Conditions

Recurrence 2Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Burkitt Lymphoma 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Immunoconjugates × Lymphoid × Clear all
NCT06796517 2025-01-28

Immunotherapy in Lymphoma

Seoul St. Mary's Hospital

Recruiting
72 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Terminated
1 enrolled 5 charts
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT01671813 2013-07-25

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡